Travere Therapeutics (TVTX) Return on Sales (2014 - 2026)

Travere Therapeutics' Return on Sales history runs 13 years deep, the most recent figure standing at 0.0% for Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.03%, up 3.0% from the prior year.
• Return on Sales was 0.0% for Q1 2026 at Travere Therapeutics, up from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.06% in Q3 2023 and bottomed at 0.0% in Q4 2025.
• A 5-year average of 0.01% and a median of 0.0% in 2024 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2023 — Return on Sales climbed 6 bps — and 2024, when it decreased 6 bps.
• Travere Therapeutics' Return on Sales stood at 0.01% in 2022, then slumped by 105 bps to 0.0% in 2023, then jumped by 99 bps to 0.0% in 2024, then plunged by 34933 bps to 0.0% in 2025, then surged by 94 bps to 0.0% in 2026.
• Business Quant data shows TVTX's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.